Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl

PL EN


Preferences help
enabled [disable] Abstract
Number of results

Journal

2012 | 7 | 4 | 525-528

Article title

Chronic Idiopathic Thrombocytopenic Purpura in children: predictive factors and outcome

Content

Title variants

Languages of publication

EN

Abstracts

EN
Idiopathic thrombocytopenic purpura (ITP) is the most common cause of acquired thrombocytopenia in children. In 20% of cases, this condition is classified as chronic when the thrombocytopenia is persistent 6 months after diagnosis. The aim of the present study is to identify the potential factors correlating with a favorable outcome in patients with chronic ITP. Some 71 patients affected by ITP were retrospectively analyzed. Results show a higher rate of spontaneous recovery that is statistically significant for patients with platelet count at diagnosis <20,000/µL. These observations suggest the possibility to delay or avoid aggressive surgical treatment for these patients.

Publisher

Journal

Year

Volume

7

Issue

4

Pages

525-528

Physical description

Dates

published
1 - 8 - 2012
online
24 - 5 - 2012

Contributors

author
  • Division of Pediatric Oncology, Catholic University, Largo A. Gemelli 8, 00168, Roma, Italy
  • Division of Pediatric Oncology, Catholic University, Largo A. Gemelli 8, 00168, Roma, Italy
  • Division of Pediatric Oncology, Catholic University, Largo A. Gemelli 8, 00168, Roma, Italy
  • Division of Pediatric Oncology, Catholic University, Largo A. Gemelli 8, 00168, Roma, Italy
  • Division of Pediatric Oncology, Catholic University, Largo A. Gemelli 8, 00168, Roma, Italy
author
  • Division of Pediatric Oncology, Catholic University, Largo A. Gemelli 8, 00168, Roma, Italy
  • Division of Pediatric Oncology, Catholic University, Largo A. Gemelli 8, 00168, Roma, Italy
author
  • Division of Pediatric Oncology, Catholic University, Largo A. Gemelli 8, 00168, Roma, Italy
author
  • Division of Pediatric Oncology, Catholic University, Largo A. Gemelli 8, 00168, Roma, Italy
  • Division of Pediatric Oncology, Catholic University, Largo A. Gemelli 8, 00168, Roma, Italy

References

  • [1] Imbach P. Immune thrombocytopenia. In Lilleyman JS, Hann IM et al. eds. Pediatric Hematology, 2nd ed., Churchill Livingstone. 1999:437
  • [2] Dickerhoff R, von Ruecker A. The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment. J Pediatr. 2000;137(5):629–632 http://dx.doi.org/10.1067/mpd.2000.110123[Crossref]
  • [3] Kühne T, Imbach P, Bolton-Maggs PH, Berchtold W, Blanchette V, Buchanan GR. Intercontinental Childhood ITP Study Group. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet. 2001;358(9299):2122–2125 http://dx.doi.org/10.1016/S0140-6736(01)07219-1[Crossref]
  • [4] Rosthøj S, Hedlund-Treutiger I, Rajantie J, Zeller B, Jonsson OG, Elinder G et al; NOPHO ITP Working Group. Duration and morbidity of newly diagnosed idiopathic thrombocytopenic purpura in children: a prospective Nordic study of an unselected cohort. J Pediatr. 2003;143(3):302–307 http://dx.doi.org/10.1067/S0022-3476(03)00245-2[Crossref]
  • [5] Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995–1008 http://dx.doi.org/10.1056/NEJMra010501[Crossref]
  • [6] Kühne T, Buchanan GR, Zimmerman S, Michaels LA, Kohan R, Berchtold W et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr. 2003;143(5):605–608 http://dx.doi.org/10.1067/S0022-3476(03)00535-3[Crossref]
  • [7] Watts RG. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the Children Hospital of Alabama. Clin Pediatr (Phila). 2004;43(8):691–702 http://dx.doi.org/10.1177/000992280404300802[Crossref]
  • [8] Psaila B, Petrovic A, Page LK, Menell J, Schonholz M, Bussel JB. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP):study of 40 cases. Blood. 2009;114:4777–4783 http://dx.doi.org/10.1182/blood-2009-04-215525[Crossref]
  • [9] Medeiros D, Buchanan GR. Major hemorrhage in children with idiopathic thrombocytopenic purpura: Immediate response to therapy and longterm outcome. J Pediatr. 1998;133(3):334–339 http://dx.doi.org/10.1016/S0022-3476(98)70265-3[Crossref]
  • [10] Lilleyman JS. Chronic childhood idiopathic thrombocytopenic purpura. Bailliere’s Clinical Haematology. 2000;13(3):469–483
  • [11] Ruggiero A, Annunziata ML, Lazzareschi I, Ridola V, Attinà G, Riccardi R. Chronic idiopathic thrombocytopenic purpura in children: case reports of spontaneous recovery without splenectomy. Ped Hem Onc. 2006; 23:471–475 http://dx.doi.org/10.1080/08880010600803123[Crossref]
  • [12] Medeiros D, Buchanan GR. Controversies in the management of idiopathic thrombocytopenic purpura during childhood. Pediatr Clin North Am. 1996;43:757–772 http://dx.doi.org/10.1016/S0031-3955(05)70431-4[Crossref]
  • [13] Lowe EJ, Buchanan GR. Idiopathic thrombocytopenic purpura diagnosed during the second decade of life. J Pediatr. 2002;141:253–258 http://dx.doi.org/10.1067/mpd.2002.125909[Crossref]
  • [14] Bolton-Maggs PHB. Idiopathic thrombocytopenic purpura. Arch Dis Child. 2000; 83:220–222 http://dx.doi.org/10.1136/adc.83.3.220[Crossref]
  • [15] Eden OB, Lilleyman JS. Guidelines for management of idiopathic thrombocytopenic purpura. The British Paediatric Haematology Group. Arch Dis Chil. 1992; 67:1056–1058 http://dx.doi.org/10.1136/adc.67.8.1056[Crossref]
  • [16] Bansal D, Bhamare TA, Trehan A, Ahluwalia J, Varma N, Marwaha RK. Outcome of chronic idiopathic thrombocytopenic purpura in children. Pediatr Blood Cancer. 2010; 54:403–407 http://dx.doi.org/10.1002/pbc.22346[Crossref]

Document Type

Publication order reference

Identifiers

YADDA identifier

bwmeta1.element.-psjd-doi-10_2478_s11536-012-0011-2
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.